SIGHT SCIENCES INC

SGHTNASDAQ

🏆 #2738 by market capEarnings Nov 5US Equity

$8.10▲ $0.37 (+4.52%)

Live

1h—

24h▲ 4.5%

7d▲ 46.5%

14d▲ 51.7%

30d▲ 51.7%

1y▲ 90.8%

🏦Market Cap

$441M

Small Cap

📈Revenue Growth (YoY)

-3.1%

Declining

📊Gross Margin

88.0%

High

💵FCF Margin

-36.5%

Thin

⚖️P/S Ratio

5.1x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $7.99 – $8.15
52-Week Range: $3.19 – $9.24
Volume: $2.01B
Avg Volume: $2.10B
Shares Outstanding: 54.4M
Next Earnings: Sep 29, 2026

Fundamentals Snapshot

Annual Revenue: $77M
Last Q Revenue: $23M
P/E Ratio: -13.9
P/S Ratio: 5.1x
EPS (TTM): $-0.55
Dividend Yield: 0.00%

Why Investors Own SGHT

✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
✓Healthy economics — 61% gross margin and 16% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$77M▲ +44.9% YoY

Gross Margin (TTM)

60.6%▲ +3.5% YoY

Operating Income (TTM)

$10M▲ +44.9% YoY

Free Cash Flow (TTM)

$12M▲ +44.9% YoY

About SIGHT SCIENCES INC

Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.

🦦